Therapeutic Asset Ratings
145 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Rilvegostomig
renal cell carcinoma
AstraZeneca
P1/2
CC
(41)
Ruxolitinib
renal cell carcinoma
University of California, San Diego
P1/2
CC
(41)
Trastuzumab Deruxtecan
renal cell carcinoma
AstraZeneca
P1/2
CC
(41)
Cdx-585
renal cell carcinoma
Celldex Therapeutics
P1
CC
(40)
Lorigerlimab
renal cell carcinoma
MacroGenics
P1
CC
(40)
Sasanlimab
renal cell carcinoma
Stephanie Berg
P2
C
(39)
[111in]-fpi-2107
renal cell carcinoma
AstraZeneca
P1
C
(37)
[18f]pt2385
renal cell carcinoma
Orhan Kemal Oz
P1
C
(37)
[225ac]-fpi-2068
renal cell carcinoma
AstraZeneca
P1
C
(37)
Acc-1898
renal cell carcinoma
AccSalus Biosciences, Inc.
P1
C
(37)
ai-061
renal cell carcinoma
OncoC4, Inc.
P1
C
(37)
bmc128
renal cell carcinoma
Biomica Ltd.
P1
C
(37)
BMS-986506
renal cell carcinoma
Bristol-Myers Squibb
P1
C
(37)
Bpi-452080
renal cell carcinoma
Betta Pharmaceuticals Co., Ltd.
P1
C
(37)
cht101
renal cell carcinoma
Zhejiang University
P1
C
(37)
Dcc-2812
renal cell carcinoma
Deciphera Pharmaceuticals, LLC
P1
C
(37)
Emunkitug
renal cell carcinoma
HiFiBiO Therapeutics
P1
C
(37)
Etakafusp Alfa
renal cell carcinoma
Asher Biotherapeutics, Inc.
P1
C
(37)
Fpi-2053
renal cell carcinoma
AstraZeneca
P1
C
(37)
Gcar1
renal cell carcinoma
Canadian Cancer Trials Group
P1
C
(37)
hc-7366
renal cell carcinoma
HiberCell, Inc.
P1
C
(37)
hfb200603
renal cell carcinoma
HiFiBiO Therapeutics
P1
C
(37)
hh160
renal cell carcinoma
Huahui Health
P1
C
(37)
hlx17
renal cell carcinoma
Shanghai Henlius Biotech
P1
C
(37)
hs-10516
renal cell carcinoma
Jiangsu Hansoh Pharmaceutical Co., Ltd.
P1
C
(37)
Showing 76 to 100 of 145 assets
Previous
Page 4 of 6
Next
